Your browser doesn't support javascript.
loading
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir, Matthew R; Bakris, George L; Gross, Coleman; Mayo, Martha R; Garza, Dahlia; Stasiv, Yuri; Yuan, Jinwei; Berman, Lance; Williams, Gordon H.
Afiliación
  • Weir MR; Division of Nephrology, Department of Medicine, University of Maryland, Baltimore, Maryland, USA. Electronic address: mweir@medicine.umaryland.edu.
  • Bakris GL; University of Chicago, Chicago, Illinois, USA.
  • Gross C; Relypsa, Redwood City, California, USA.
  • Mayo MR; Relypsa, Redwood City, California, USA.
  • Garza D; Relypsa, Redwood City, California, USA.
  • Stasiv Y; Relypsa, Redwood City, California, USA.
  • Yuan J; Relypsa, Redwood City, California, USA.
  • Berman L; Relypsa, Redwood City, California, USA.
  • Williams GH; Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Kidney Int ; 90(3): 696-704, 2016 09.
Article en En | MEDLINE | ID: mdl-27350174
Elevated serum aldosterone can be vasculotoxic and facilitate cardiorenal damage. Renin-angiotensin system inhibitors reduce serum aldosterone levels and/or block its effects but can cause hyperkalemia. Patiromer, a nonabsorbed potassium binder, decreases serum potassium in patients with chronic kidney disease on renin-angiotensin system inhibitors. Here we examined the effect of patiromer treatment on serum aldosterone, blood pressure, and albuminuria in patients with chronic kidney disease on renin-angiotensin system inhibitors with hyperkalemia (serum potassium 5.1-6.5 mEq/l). We analyzed data from the phase 3 OPAL-HK study (4-week initial treatment phase of 243 patients; 8-week randomized withdrawal phase of 107 patients). In the treatment phase, the (mean ± standard error) serum potassium was decreased concordantly with the serum aldosterone (-1.99 ± 0.51 ng/dl), systolic/diastolic blood pressure (-5.64 ± 1.04 mm Hg/-3.84 ± 0.69 mm Hg), and albumin-to-creatinine ratio (-203.7 ± 54.7 mg/g), all in a statistically significant manner. The change in the plasma renin activity (-0.44 ± 0.63 µg/l/hr) was not significant. In the withdrawal phase, mean aldosterone levels were sustained with patiromer (+0.23 ± 1.07 ng/dl) and significantly increased with placebo (+2.78 ± 1.25 ng/dl). Patients on patiromer had significant reductions in mean systolic/diastolic blood pressure (-6.70 ± 1.59/-2.15 ± 1.06 mm Hg), whereas those on placebo did not (-1.21 ± 1.89 mm Hg/+1.72 ± 1.26 mm Hg). Significant changes in plasma renin activity were found only in the placebo group (-3.90 ± 1.41 µg/l/hr). Thus, patiromer reduced serum potassium and aldosterone levels independent of plasma renin activity in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polímeros / Sistema Renina-Angiotensina / Aldosterona / Insuficiencia Renal Crónica / Hiperpotasemia / Hipertensión Tipo de estudio: Clinical_trials / Etiology_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Kidney Int Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polímeros / Sistema Renina-Angiotensina / Aldosterona / Insuficiencia Renal Crónica / Hiperpotasemia / Hipertensión Tipo de estudio: Clinical_trials / Etiology_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Kidney Int Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos